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Association of Insulin Resistance, Hyperleptinemia, and
Impaired Nitric Oxide Release With In-Stent Restenosis in
Patients Undergoing Coronary Stenting
PierMarco Piatti, MD; Carlo Di Mario, MD; Lucilla D. Monti, MD; Gabriele Fragasso, MD;
Fabio Sgura, MD; Andrea Caumo, MD; Emanuela Setola, MD; Pietro Lucotti, MD;
Elena Galluccio, PhD; Cristina Ronchi, PhD; Anna Origgi, MD; Ivana Zavaroni, MD;
Alberto Margonato, MD; Antonio Colombo, MD
Background—Previously undiagnosed diabetes, impaired glucose tolerance, and insulin resistance are common in patients
with acute myocardial infarction and coronary heart disease (CHD) and might be involved in early restenosis after stent
implantation. To evaluate whether markers of insulin resistance syndrome, including leptin, and endothelial dysfunction
are related to increased rate of early restenosis, we studied nondiabetic patients with CHD after successful coronary
stenting.
Methods and Results—Both patients with CHD undergoing coronary stenting (120 patients) and control subjects (58
patients) were submitted to an oral glucose tolerance test (OGTT). Fasting leptin levels and fasting and postglucose load
insulin sensitivity were assessed. Endothelial function was measured by nitrite and nitrate release (NOx) during OGTT.
More than 50% of patients treated with stent implantation presented impaired glucose tolerance or type 2 diabetes, which
was previously undiagnosed. These patients also had higher glucose, insulin, and leptin levels than control subjects.
Among the stented patients, insulin and leptin levels were higher in patients with restenosis than in patients without
restenosis. A significant increase in NOx levels was found during OGTT both in patients without restenosis and in
control subjects. On the contrary, NOx profiles were blunted in patients with restenosis. At multiple regression analysis,
only AUC-NOx areas and insulin sensitivity index showed an independent correlation with the minimal lumen
diameter at follow-up.
Conclusions—We demonstrated that insulin resistance and endothelial dysfunction are independent predictors of early
restenosis after coronary stenting. (Circulation. 2003;108:2074-2081.)
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Recent serial intravascular ultrasound studies in nondia-betic patients showed that neointimal tissue proliferation
after stent implantation was greater in patients with impaired
glucose tolerance than in patients with normal glucose toler-
ance at follow-up and that the best predictor of restenosis was
the sum of insulin levels after oral glucose tolerance test
(OGTT).1 Another cause of restenosis might be a reduced
synthesis of NO (NOx), because NOx has been demonstrated
to decrease migration and proliferation of vascular smooth
muscle cells to attenuate binding of inflammatory cells to the
vascular wall, inhibit thrombosis by reducing platelet adhe-
sion and aggregation, and maintain vascular relaxation.2–4
In addition, leptin, a hormone related to fat metabolism and
insulin resistance (IR), has been recognized as an independent
risk factor for coronary heart disease in a large cohort of the
West of Scotland (WOSCOPS).5 Moreover, leptin has
emerged as a metabolic hormone that contributes importantly
to regulation of vascular biology, and it was reported that
leptin modulates endothelial NO synthesis.6,7
The aim of this study was to evaluate the relationships
between IR, leptin levels, and endothelial function, evaluated
as NOx release during OGTT, and the degree of restenosis 6
months after successful coronary stenting in nondiabetic
patients with coronary heart disease (CHD).
Methods
Subjects
We enrolled 120 consecutive patients (mean age, 59.01.4 years;
mean body mass index [BMI], 25.70.7 kg/m2) routinely submitted
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to angiographic control 6 months after successful coronary stenting.
Previous diagnosis of type 2 diabetes mellitus was excluded. Among
the whole group, the 46 patients with restenosis, defined as recur-
rence and then 50% diameter reduction in the segment treated,
showed a minimal lumen diameter (MLD) at follow-up of 0.950.49
versus 2.650.62 mm in the group without restenosis (74 patients).
After a standard oral glucose test (75 g), 16 patients with restenosis
and 35 patients without restenosis showed plasma glucose concen-
trations diagnostic for type 2 diabetes at 2 hours postload; 12 patients
with restenosis and 14 patients without restenosis had an impaired
glucose tolerance (IGT), whereas 18 patients with restenosis and 25
patients without restenosis demonstrated a normal glucose tolerance
(NGT).
Because type 2 diabetes mellitus has well-known detrimental
effects on insulin resistance and endothelial dysfunction, we chose to
focus our attention on NGT or IGT CHD patients. To this aim, we
evaluated 30 patients with restenosis and 39 patients without
restenosis matched for age, gender, successful coronary stenting of a
single coronary stenosis, no previous history of diabetes mellitus,
normal fasting glucose, normal glycohemoglobin, cholesterol, HDL
cholesterol and triglyceride levels, normal systolic and diastolic
blood pressure levels, and similar antilipidemic and antihypertensive
therapy. Their clinical and metabolic characteristics are depicted in
Table 1.
A standard OGTT was also performed in 58 nondiabetic and
non-CHD control subjects, matched with CHD patients for age,
gender, weight, BMI, systolic and diastolic pressure, triglyceride,
and HDL cholesterol (Table 1). All control subjects showed a normal
response after the glucose challenge. All subjects gave informed
consent to participate in the study, and the local ethics committee
approved the protocol.
Methods
Stent Implantation and Clinical and Angiographic
Follow-Up
Patients with CHD submitted to the procedure were treated with IV
heparin and combined antiplatelet therapy, whereas IIb/IIIa inhibi-
tors were used at the operator’s discretion. Customized stents
mounted on expandable balloon from Phitis Diamond Plus Stent
were implanted. A minimal balloon inflation pressure of 14 atm was
recommended.
After 6 months, patients were scheduled for control angiography.
Other angiographic examinations performed before 6 months for
recurrence of symptoms were used only if restenosis was present.
Quantitative coronary angiography analysis was performed using a
validated automated edge-detection program (CMS version 5.2,
MEDIS). MLD, length of stenosis, and percentage diameter stenosis
after 6 months were measured. In addition, the following parameters
were assessed: acute gain, MLD after the procedure minus MLD
before the procedure; late loss, MLD after the procedure minus MLD
at follow-up; net gain, difference between acute gain and late loss;
and restenosis, presence of 50% stenosis at follow-up. Results of
all the parameters before and after stent implantation and at 6-month
angiographic follow-up are reported in Table 2.
OGTT and Measurement of Insulin Sensitivity
At 8:00 AM, after a 10- to 12-hour overnight fast, all subjects
received a 75-g OGTT. Arterialized blood samples, taken without
tourniquet, were withdrawn at 0, 30, 60, and 120 minutes for
measurement of plasma glucose, insulin, and NOx concentrations.
In particular, for NOx evaluation, in a previous study we demon-
strated that arterialized NOx levels are a reliable index of forearm
arterial levels, because there was a highly significant correlation
TABLE 1. Clinical and Metabolic Characteristics of 69 Patients With CHD
Submitted to Stenting Procedures and 58 Control Subjects (MeanSD)
Patients With
Restenosis
(N30)
Patients Without
Restenosis
(N39)
Control
Subjects
(N58)
Age, y 55.810.4 58.710.0 57.16.9
Weight, kg 78.315.9 73.26.9 73.713.7
BMI, kg/m2 27.14.4 25.61.9 26.83.8
Waist/hip ratio 0.960.11 0.970.06 0.950.08
Systolic blood pressure, mm Hg 13016 13412 12715.2
Diastolic blood pressure, mm Hg 816 8312 808
Glucose, mg/dL 104.115.9 98.019.4 97.410.7
Insulin, U/mL 10.86.4*† 8.02.3 6.83.5
HOMA index 2.811.99*† 1.930.59 1.680.95
NOx, mol/L 23.110.3† 18.917.3 14.713.9
Leptin, ng/mL 8.25.5*† 5.23.8 5.04.6
Cholesterol, mg/dL 18544 19350 20038
HDL cholesterol, mg/dL 5016 4314 481.2
Triglyceride, mg/dL 14555 14275 14745
Oral antiplatelet drugs, n (%) 30 (100) 39 (100)   
-blockers, n (%) 20 (66) 24 (62)   
ACE inhibitors, n (%) 14 (47) 18 (46)   
Statins, n (%) 19 (64) 25 (64)   
Long-term treatment 9 15   
6-month treatment 10 10   
ACE indicates angiotensin-converting enzyme.
*P0.05 patients with restenosis vs patients without restenosis.
†P0.05 patients with restenosis vs control subjects.
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between arterial and arterialized NOx levels (r0.90, P0.001;
slope, 0.930.11; P0.16 versus a slope of 1.0; intercept,
1.322.86; P0.11 versus an intercept of 0).8
In addition, in a pilot study, arterialized blood samples were taken
every 10 minutes over 1 hour in 7 fasting subjects. NOx levels
remained stable during this period, with intrasubject coefficient of
variation (CV) values ranging from 3.7% to 8.5% (mean CV,
5.81.8%), suggesting that NOx levels remain constant over time in
fasting subjects not submitted to an OGTT. At time 0, blood samples
were also taken for measurement of leptin, glycohemoglobin, tri-
glycerides, HDL cholesterol, and total cholesterol.
Assays
Blood glucose, glycohemoglobin, triglycerides, HDL cholesterol,
and total cholesterol were measured with spectrophotometric meth-
ods adapted to Cobas Fara II using commercial kits (Unimate,
Roche). Serum insulin levels were assayed with a microparticle
enzyme immunoassay (IMX; Abbott Laboratories).
NOx levels were evaluated through the measurement of metabolic
end products, ie, nitrite and nitrate, using enzymatic catalysis
coupled with Griess reaction, as reported by Verdon et al,9 with an
intra-assay CV of 4.1% and an interassay CV of 9.7%. Leptin levels
were measured with an ELISA kit (Linco Research, Inc).
Measurement of Insulin Sensitivity and Insulin Secretion
We used 2 different methods to assess insulin sensitivity in the 3
study groups. One is based on the baseline glucose and insulin data,
whereas the other exploits the dynamic glucose and insulin data
measured during the OGTT. We used the fasting glucose and insulin
values to calculate the homeostasis model assessment index of IR
(HOMA-IR) according to the following formula: HOMA-
IR[baseline insulin concentration (U/mL) · baseline glucose
concentration (mmol/L)/22.5].10
We used the glucose and insulin determinations during the OGTT
to calculate an index of insulin sensitivity, defined as SI (oral)
(104dL kg1min1/U mL1). The calculation of SI (oral) hinges on
the intuitive notion that the glucose and insulin excursions during the
OGTT reflect the degree of IR of the subject receiving the test. For
instance, a large glucose excursion, accompanied by a large insulin
excursion, indicates the presence of IR. This notion has been put on
firm theoretical grounds using a mathematical model of the glucose
insulin system (the so-called minimal model).11 The model allows
derivation of a formula for insulin sensitivity based on the area under
the curve (AUC) of glucose and insulin concentrations during the
OGTT.12,13
Insulin secretion was evaluated in the 3 study groups by calculat-
ing the AUC of the incremental (above basal) insulin excursion
during the OGTT (AUC insulin area). All AUCs were calculated
using the trapezoidal method.
In addition, to obtain an objective characterization of the relation-
ship between insulin sensitivity and insulin secretion, we performed
a hyperbolic regression by fitting the experimental data to the
following hyperbolic function: AUC insulin areap1p2/SI oral.
The unknown parameters p1 and p2 were estimated using the
Nonlinear Curve Fitting Module of the JMP statistical software (SAS
Institute, Inc).
Statistical Analysis
All values are expressed as meanSD at each time interval.
Comparisons among groups were performed using 1-way ANOVA
followed by the Scheffé F test when appropriate. A 2-tailed P level
of less than 0.05 was considered statistically significant. Triglyceride
levels were logarithmically transformed to correct for skewness and
subsequently backtransformed to their natural units for presentation
in the tables. Simple and multiple regression analyses was performed
with MLD at follow-up as the dependent variable and all other
parameters as independent variables.
Results
In the fasting state, insulin, HOMA index (marker of insulin
resistance), NOx, and leptin levels were significantly higher
in patients treated with stent implantation (with or without
restenosis) than in control subjects, whereas glucose levels
were similar in the 3 groups. Among the patients who
underwent stent implantation, patients with restenosis showed
higher insulin and HOMA levels than patients without reste-
TABLE 2. Quantitative Angiographic Evaluation in 69 Patients at 6-Month
Angiographic Follow-Up (MeanSD)
Patients With
Restenosis
(N30)
Patients Without
Restenosis
(N39)
P
Values
Reference diameter, mm
Before 2.910.55 2.990.69 0.57
After 3.060.49 3.220.62 0.25
Follow-up 2.730.55 2.990.62 0.10
Minimal luminal diameter, mm
Before 0.780.55 0.770.50 0.96
After 2.650.60 2.870.62 0.14
Follow-up 0.950.49 2.550.62 0.0001
Diameter stenosis, %
Before 72.616.4 73.115.0 0.88
After 14.111.5 9.715.6 0.20
Follow-up 64.216.4 16.512.5 0.0001
Length stenosis, mm
Before 10.18.2 9.87.5 0.87
Follow-up 14.214.7 5.43.7 0.0008
Acute gain, mm 1.840.60 2.110.69 0.10
Late loss, mm 1.700.66 0.360.56 0.0001
Net gain (mm) 0.140.60 1.750.69 0.0001
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nosis, suggesting a state of fasting IR in the presence of
increased leptin levels (Table 1).
Table 3 shows the pattern of plasma glucose, insulin, and
NOx levels during OGTT in patients with and without
restenosis and in control subjects, whereas Figure 1 shows SI
oral values, insulin incremental areas, and NOx incremental
areas during OGTT. Patients with or without restenosis
showed higher glucose levels than control subjects, but the
profile was identical in the 2 groups (Table 3, top). Both
groups of CHD patients with or without restenosis were
markedly more insulin resistant than control subjects, as
demonstrated by the low SI oral, even if patients with
restenosis were significantly more insulin resistant than
patients without restenosis (Figure 1, top).
Interestingly, even if both CHD patients groups were
hyperinsulinemic after the glucose load, insulin levels were
markedly higher in patients with restenosis than in patients
without restenosis (Table 3, middle). This result was also
displayed by the evaluation of insulin incremental areas
(Figure 1, middle) that was increased by approximately 80%
and 30% in patients with and without restenosis, respectively,
compared with control subjects, suggesting that CHD patients
with restenosis had the highest insulin secretion to maintain
similar glucose pattern.
NOx profiles were blunted in patients with restenosis,
whereas a significant increase in NOx levels was demon-
strated after OGTT both in patients without restenosis and in
control subjects (Table 3, bottom). A negative AUC-NOx
area was observed in patients with restenosis, whereas a
similar positive increment was found in patients without
restenosis and in control subjects (Figure 1, bottom).
Taking all CHD patients together, at simple regression anal-
ysis, MLD at follow-up significantly correlated with SI oral
(r0.39, P0.001), HOMA (r0.23, P0.05), leptin levels
(r0.26; P0.03), and AUC-NOx areas (r0.40, P0.0006).
At multiple regression analysis, in which all of the clinical and
metabolic variables associated with the IR syndrome were
included, only AUC-NOx areas (P0.0079) and insulin sen-
sitivity index (SI oral; P0.0207) remained independently
correlated with MLD at follow-up (Table 4).
To rule out the influence of endothelial dysfunction on
restenosis independently of the role of hyperinsulinemia, we
analyzed a subgroup of patients (22 patients with restenosis
and 22 patients without restenosis) matched for insulin
sensitivity (SI oral), insulin secretion during OGTT, and all
other metabolic variables (Table 5). Also in this selected
matched subgroup, leptin levels were higher and the AUC-
NOx was significantly lower in patients with restenosis
compared with patients without restenosis.
Discussion
Restenosis constitutes an important limitation after stent
implantation, but its pathogenesis is not yet fully understood.
The results of the present study strongly suggest that a lack of
NOx release after OGTT, increased leptin levels, hyperinsu-
linemia, and IR are important predictors of restenosis after
coronary stenting in CHD patients with normal fasting
glucose and glycated hemoglobin levels.
Influence of NOx on Restenosis After
Coronary Stenting
In our opinion, the most striking result of the present study is
that patients with CHD and restenosis have an important
TABLE 3. Time Course of Plasma Glucose, Serum Insulin, and Plasma NOx
Levels After OGTT in 69 Patients With CAD (With and Without Restenosis 6
Months After Stenting Implantation) and in 58 Control Subjects (MeanSD)
Patients With
Restenosis
(N30)
Patients Without
Restenosis
(N39)
Control
Subjects
(N58)
Glucose, mg/dL
0 104.115.9 98.019.4 97.410.7
30 172.433.6* 168.534.2† 118.321.8
60 194.349.1* 197.746.6† 139.236.6
120 148.448.4* 151.249.6† 98.820.1
Insulin, U/mL
0 10.86.4*‡ 8.02.3 6.83.5
30 71.237.6*‡ 52.332.3† 37.020.0
60 100.173.0* 75.032.3 67.538.8
120 80.675.6*‡ 51.234.6 31.924.1
NOx, mol/L
0 23.110.3* 18.917.3 14.713.9
30 20.212.3 23.317.4 16.29.8
60 19.711.6 21.615.5 17.89.6
120 17.512.2 17.013.2 14.312.3
*P0.05 patients with restenosis vs control subjects.
†P0.05 patients without restenosis vs control subjects.
‡P0.05 patients with restenosis vs patients without restenosis.
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impairment of endothelial function, as suggested by increased
fasting NOx levels and by the lack of NOx release during
OGTT.
The increase in fasting NOx levels has been already
reported in insulin-resistant subjects,14–16 and recently our
group demonstrated that not only type 2 diabetic patients but
also control subjects carrying 2 single nucleotide variants of
endothelial NO synthase gene (E298D and IVS1827A/C)
had increased fasting NOx levels in the presence of IR,
suggesting a common trait unifying IR syndrome and cardio-
vascular disease.17
The impairment of NOx release during OGTT in patients
with restenosis was never, to our knowledge, previously
demonstrated. This finding supports previous data in which
restenosis was related to impaired NO production by the
damaged endothelium.18 Furthermore, Wu et al19 showed that
patients with in-stent restenosis 6 months after coronary
stenting had impaired NO-dependent endothelial vasodilation
compared with patients without restenosis.
Even if the biological explanation for decreased NOx
levels during OGTT is difficult to explain, some hypotheses
can be put forward. Patients with restenosis might have a
greater increase in circulating vasoconstrictor agents, like
endothelin-1, because endothelin-1 significantly inhibits NOx
release by vascular smooth muscle cells after different stim-
uli.20 Our group has previously suggested that a decrease of
endothelin-1 levels, induced by L-arginine infusion, was able
to restore insulin-induced NOx release in subjects with
cardiovascular syndrome X.21
A negative correlation between leptin levels and AUC-
NOx (r0.28; P0.04; data not shown) was demonstrated
and might support previous data by Cooke et al,22 who
postulated that the long-term consequence of hyperleptinemia
is a reduction of NO synthesis attributable to the increased
oxidative stress in endothelial cells. Still, the understanding
of the molecular mechanisms that determine the impairment
of NOx release in patients with restenosis is highly specula-
tive and was beyond the scope of the present study. To solve
this important issue, additional investigations are needed.
A limitation of our study could be that we measured
plasma NOx concentrations from arterialized samples. It has
been previously demonstrated that plasma NOx may not
provide an accurate estimate of total NOx in blood because of
different CO2/bicarbonate concentrations in venous sam-
ples.23 However, we previously demonstrated a close rela-
tionship between arterialized and arterial samples (as reported
in Methods) and demonstrated a very low arterialized CO2
variability over time (CV, 2.00.3%).8 Thus, we are quite
confident that our results, suggesting a defect of NOx release
during OGTT in patients with restenosis, are correct.
Figure 1. SI oral index (top), AUC insulin areas (middle), and
AUC NOx areas (bottom) after OGTT (meanSD). Black histo-
grams represent patients with restenosis (n30); gray histograms,
patients without restenosis (n39); and white histograms, control
subjects (n58).
TABLE 4. Multiple Regression Analysis With Minimal Lumen
Diameter at 6-Month Follow-Up After Stenting as the
Dependent Variable (r0.577; P<0.04)
 Coefficient F Ratio
P
Values
-AUC NOx 0.001 7.651 0.0079
SI oral index 0.094 5.707 0.0207
Leptin 0.06 1.073 0.305
HOMA index 0.034 0.053 0.819
Waist/hip ratio 2.07 0.614 0.437
BMI 0.031 0.249 0.619
Triglycerides 0.005 2.041 0.159
Systolic blood pressure 0.012 0.548 0.463
Diastolic blood pressure 0.020 0.659 0.421
Age 0.004 0.038 0.845
Reference diameter before stenting 0.030 0.008 0.928
Stenosis length before stenting 0.032 1.207 0.277
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Influence of Increased Leptin Levels on Restenosis
After Coronary Stenting
Another interesting result of the present study is the fact that
increased leptin levels were present in patients with restenosis
after stenting whereas superimposable results were demon-
strated in patients without restenosis and in control subjects.
Our data seem to reinforce the role for leptin as an index of
chronic inflammation, participating in the atherogenic pro-
cess.24 After the first demonstration in WOSCOPS5 of a role
of leptin as an independent risk factor for coronary heart
disease, recent studies have confirmed the role of leptin in
cardiovascular and cerebrovascular disease.25,26
It is well-known that other parameters, such as C-reactive
protein (CRP), are predictive of restenosis. In fact, recently
the IMPRESS Study27 showed that high CRP levels 72 hours
after successful coronary stenting is predictive of a worse
prognosis at 12 months, probably suggesting an additional
activation of the inflammatory process within the plaque
itself and as a response to injury during coronary stenting.
Moreover, CRP level at 48 hours after stent implantation in
the carotid arteries was associated with a significantly higher
6-month restenosis.28 However, we could not derive data
from this important parameter, because we did not have
samples on the initial admission to the hospital or on the days
after stent implantation.
Influence of Insulin Resistance on Restenosis After
Coronary Stenting
Another important point is that patients with CHD with or
without restenosis are markedly insulin resistant compared
with control subjects, showing that patients with restenosis
have the highest degree of IR. IR is a state in which peripheral
tissues have decreased sensitivity to insulin, leading to
increased circulating insulin levels to maintain euglycemia. In
favor of a relationship between hyperinsulinemia and coro-
nary restenosis after stenting, Takagi et al29 have shown that
neointimal index measured 6 months after coronary stenting
correlated with fasting and postglucose load insulin levels.
The concept that IR, even at the myocardial level, can
precede the onset of overt diabetes by many years has been
recently shown by Iozzo et al.30 The authors in this elegant
study demonstrated that cardiovascular disease is accompa-
nied by a generalized state of IR, involving also the normally
contracting myocardium. In fact, in type 2 diabetic patients
without cardiovascular disease, they found a severe myocar-
dial IR, because insulin-mediated glucose uptake was reduced
by 41% and a significant correlation (r0.38; P0.02) was
found between myocardial glucose uptake and the ejection
fraction. Moreover, they suggested that IR, at the level of the
myocardium, may precede and possibly cause the develop-
ment of cardiovascular disease.
In keeping with abundant evidence in the literature and as
reviewed by Kahn,31 insulin secretion is tightly linked to
insulin sensitivity, and, given their interdependence, these
variables should be considered in tandem. The relationship
between insulin sensitivity and insulin secretion in human
subjects with normal glucose tolerance demonstrates a hyper-
bolic shape, as represented in Figure 2 by the continuous line
derived on data from our 58 control subjects. The nature of
this relationship is such that, for any difference in insulin
sensitivity, a corresponding reciprocal difference occurs in
insulin response. The 2 mean values of patients with and
TABLE 5. Clinical and Metabolic Characteristics of 22 Patients With Restenosis
Matched for Insulin Sensitivity and Secretion With 22 Patients Without Restenosis
(MeanSD)
Patients With
Restenosis
(N22)
Patients Without
Restenosis
(N22) P
Age, y 54.910.3 57.69.9 NS
Weight, kg 75.18.9 73.07.0 NS
BMI, kg/m2 26.12.8 25.41.9 NS
Waist/hip ratio 0.950.09 0.960.05 NS
Systolic blood pressure, mm Hg 13219 13314 NS
Diastolic blood pressure, mm Hg 819 829 NS
Glucose, mg/dL 1009 9714 NS
Insulin, U/mL 8.83.3 8.22.3 NS
HOMA index 2.20.9 2.00.5 NS
NOx (mol/L) 24.111.3 21.421.5 NS
HbA1c, % 5.60.5 5.54.2 NS
Cholesterol, mg/dL 18747 19138 NS
HDL cholesterol, mg/dL 4824 4412 NS
Triglyceride, mg/dL 14142 13861 NS
SI oral index, 104 dL kg1min1/U mL1 7.65.2 6.22.4 NS
AUC insulin area, U/mL*60 min 59442293 62222162 NS
AUC NOx area, mol/L*60 min 445741 184769 0.01
Leptin, ng/mL 7.45.6 4.62.4 0.05
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without restenosis are both located in a steep segment of the
hyperbolic curve, where little variations in insulin sensitivity
(SI oral) induce large variations in insulin secretion (AUC
insulin area) during OGTT. Compared with patients without
restenosis, patients with restenosis show a small reduction in
insulin sensitivity but a large compensatory elevation in
insulin response during OGTT, probably reflecting their
inability to use insulin more efficiently. Thus, we can say that
glucose tolerance remains constant in these patients because
insulin sensitivity is matched by reciprocal changes in insulin
secretion. Because the hyperbolic relationship between insu-
lin sensitivity and insulin secretion has been described to act
as a potential new tool to predict individuals at a high risk of
developing diabetes,32 in our opinion, the hypothesis that
improving insulin sensitivity might reduce the incidence of
restenosis should be tested in a prospective trial.
Clinical Implications
Our results indicate that more than 50% of patients submitted
to coronary stenting for ischemic heart disease present abnor-
mal glucose levels after OGTT. Previous studies have shown
that impaired glucose tolerance not only runs the risk of
developing overt diabetes and its associated microvascular
complications but also has an increased risk of cardiovascular
morbidity and mortality compared with healthy glucose-
tolerant patients.33 Therefore, early detection of impaired
glucose tolerance would permit initiation of secondary pre-
ventive treatment measures in such patients.
Our findings, according with recent data for myocardial
infarction,34 suggest the utility to perform an OGTT, a quick,
inexpensive, and easy test, to recognize high-risk individuals
submitted to coronary stenting for ischemic heart disease at
the time of admission. The limited availability of stents
eluting antiproliferative drugs, effective in restenosis preven-
tion, suggests that these expensive prostheses should be
selectively implanted in this high-risk group.
Conclusions
In conclusion, the present study suggests that both insulin
resistance and endothelial dysfunction are independent pre-
dictors of restenosis after coronary stenting. Evaluation of
glucose tolerance, insulin secretion, and NOx release after a
standard OGTT is an important tool in the attempt to
recognize subjects at risk of early restenosis among nondia-
betic patients undergoing percutaneous coronary revascular-
ization. Furthermore, the isolated detections of insulin resis-
tance and postglucose load hyperinsulinemia, although an
important risk factor for CHD, are poor predictors of reste-
nosis after coronary stenting but are highly predictive if
associated with increased leptin levels and the loss of NOx
release during OGTT.
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